However, in cases where the mutations affect different tumor cells, a given type of TKI can only target corresponding tumor cells (eg, EGFR‐TKI can only target tumor cells with EGFR alterations), and other tumor cells (ie, not carrying the targeted mutation) may be able to proliferate rapidly. This evidence concerns the gene EGFR and neoplasm.